Phase II-Studie zur Behandlung des nicht kleinzelligen Bronchialkarzinoms im Stadium III b und IV mit der Kombination Docetaxel und Carboplatin

Abkürzungsverzeichnis 5-FU 5-Fluorouracil Abs Abstact AP Alkalische Phosphatase ASCO American Society of Clinical Oncology AUC Area under the curve B J British Journal bzw. beziehungsweise Ca Kalzium CL Chlorid CR Komplette Remission CT Computertomografie d.h. das heißt DNA Desribonukleinsäure ECOG Eastern Cooperative Oncology Group G-CSF Granulozyten Kollonie stimulierender Faktor GFR Glomeruläre Filtrationsrate ggf. gegebenenfalls GOT Glutamat-Oxalazetat-Transaminase GPT Glutamat-Pyruvat-Transaminase Gpt/l Gigapartikel pro Liter Gy Gry h Stunde Hb Hämoglobin HCG Humanes Chorion-Gonadotropin Hz Hertz i.v. intravenös LDH Lactatdehydrogenase mg Milligramm min Minuten ml Milliliter MRT Magnetresonanztomografie Na Natrium NSCLC Non small cell lung cancer PD Progrediente Erkrankung PR Partielle Remission PVC Polyvinylchlorid SCLC Small cell lung cancer SD Stabile Erkrankung SI Internationale Laboreinheiten t ½ Halbwertszeit Tab. Tabelle TNM TNM-System, Tumorklassifikation berücksichtigt T = Tumor N = Lymphknoten, M = Metastasen UV Ultraviolett WHO World Health Organisation z.B. zum Beispiel α Alpha β Beta 1

[1]  D. Carney,et al.  Chemotherapy in the management of patients with inoperable non-small cell lung cancer. , 1996, Seminars in oncology.

[2]  D. Ihde,et al.  Chemotherapy of Lung Cancer , 1992 .

[3]  W. Gregory,et al.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.

[4]  C. Lipschultz,et al.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.

[5]  R. Ozols,et al.  Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. , 1995, Seminars in oncology.

[6]  T. Constantinidis,et al.  A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. , 2001, Lung cancer.

[7]  Chris Williams.  Oncology , 1990, The Lancet.

[8]  J. Luketich,et al.  Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Vrignaud,et al.  Preclinical evaluation of docetaxel (Taxotere). , 1995, Seminars in oncology.

[10]  J G McVie,et al.  Non-small cell lung cancer: meta-analysis of efficacy of chemotherapy. , 1996, Seminars in oncology.

[11]  M. Green,et al.  Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Winn,et al.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[13]  M. Kris,et al.  Phase II trial of a 75‐mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non‐small cell lung cancer , 1995, Cancer.

[14]  R. A. Joss,et al.  Die Chemotherapie der nicht-kleinzelligen Bronchuskarzinome , 1985 .

[15]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T le Chevalier.  Chemotherapy for advanced NSCLC. Will meta-analysis provide the answer? , 1996, Chest.

[17]  J. Díaz,et al.  Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. , 1993, Biochemistry.

[18]  Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. , 1997, American journal of respiratory and critical care medicine.

[19]  J. Bernhard,et al.  Patients' estimation of overall treatment burden: why not ask the obvious? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Earl,et al.  Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer , 2004, Cancer Chemotherapy and Pharmacology.

[21]  J. Jassem.  Chemotherapy of advanced non-small cell lung cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Crowley,et al.  A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[24]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[25]  T. Rosengart.  Seminars in Thoracic and Cardiovascular Surgery , 2005 .

[26]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[27]  R. Doll,et al.  The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. , 1981, Journal of the National Cancer Institute.

[28]  C. Hennequin,et al.  S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. , 1995, British Journal of Cancer.

[29]  S. Rodenhuis,et al.  The use of the Calvert formula to determine the optimal carboplatin dosage , 2005, Journal of Cancer Research and Clinical Oncology.

[30]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[31]  J. Schiller.  Role of taxanes in lung-cancer chemotherapy. , 1998, Cancer investigation.

[32]  D. Ettinger,et al.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Radulović,et al.  Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. , 2001, Lung cancer.

[34]  H. Becher,et al.  Effect of tobacco smoking on various histological types of lung cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[35]  C. Mountain,et al.  The international system for staging lung cancer. , 2000, Seminars in surgical oncology.

[36]  P. Potier,et al.  Therapeutic response to taxol of six human tumors xenografted into nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[37]  T Anderson,et al.  Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. , 1993, Journal of the National Cancer Institute.

[38]  S. Ricci,et al.  A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. , 1997, Seminars in oncology.

[39]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.

[40]  R. James,et al.  Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer. , 1999, Seminars in oncology.

[41]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[42]  L. Kolonel,et al.  Vegetable consumption and lung cancer risk: a population-based case-control study in Hawaii. , 1989, Journal of the National Cancer Institute.

[43]  J. Rigas,et al.  Docetaxel in stage III and IV non-small cell lung cancer. , 1995, European journal of cancer.

[44]  N. Prajda,et al.  Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. , 1993, Cancer biochemistry biophysics.

[45]  C. Belani.  Use of Docetaxel and Carboplatin for Patients With Non-Small-Cell Lung Cancer , 1997 .

[46]  D. Karnofsky,et al.  The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .

[47]  C. Belani.  Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. , 1999, Seminars in oncology.

[48]  K. Mattson,et al.  Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer. , 1997, Seminars in oncology.

[49]  G Fountzilas,et al.  Paclitaxel and carboplatin in inoperable non-small cell lung cancer. , 1996, Seminars in oncology.

[50]  M Lavandier,et al.  Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.

[51]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. Finkelstein,et al.  Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  E. Vokes,et al.  Phase I study of docetaxel with concomitant thoracic radiation therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.

[55]  C. Sweeney,et al.  Chemotherapy in Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[56]  J. Rigas.  SINGLE-AGENT DOCETAXEL IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG CANCER , 1997 .

[57]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.